Patents by Inventor Helen Kim Cho

Helen Kim Cho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190142918
    Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
    Type: Application
    Filed: January 18, 2019
    Publication date: May 16, 2019
    Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
  • Patent number: 10251944
    Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: April 9, 2019
    Assignee: Pfizer Inc.
    Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
  • Publication number: 20190083612
    Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Application
    Filed: November 12, 2018
    Publication date: March 21, 2019
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: YASMINA NOUBIA ABDICHE, HELEN KIM CHO, WEIHSIEN HO, KAREN UTE JOOSS, ARVAND RAJPAL, SAWSAN YOUSSEF
  • Publication number: 20190038728
    Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.
    Type: Application
    Filed: August 8, 2018
    Publication date: February 7, 2019
    Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai, James Richard Merson
  • Publication number: 20190016775
    Abstract: The present disclosure provides: (a) isolated immunogenic CEA polypeptides; (b) isolated nucleic acid molecules encoding (i) an immunogenic CEA polypeptide, (ii) an immunogenic CEA polypeptide and an immunogenic MUC1 polypeptide, (iii) an immunogenic CEA polypeptide and an immunogenic TERT polypeptide, or (iv) an immunogenic CEA polypeptide, an immunogenic MUC1 polypeptide, and an immunogenic TERT polypeptide; (c) compositions comprising an isolated nucleic acid molecule; and (d) methods relating to uses of the immunogenic CEA polypeptides, nucleic acid molecules, and compositions.
    Type: Application
    Filed: July 9, 2018
    Publication date: January 17, 2019
    Inventors: Joseph John Binder, Helen Kim Cho, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Marianne Marcela Andrea Martinic
  • Publication number: 20170202938
    Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
    Type: Application
    Filed: January 17, 2017
    Publication date: July 20, 2017
    Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
  • Publication number: 20160375115
    Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.
    Type: Application
    Filed: July 11, 2016
    Publication date: December 29, 2016
    Inventors: Joseph John BINDER, Helen Kim CHO, Michael Robert DERMYER, Karin Ute JOOSS, Brian Gregory PIERCE, Joyce Tsi TAN, Van To TSAI
  • Patent number: 9468672
    Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: October 18, 2016
    Assignee: Pfizer Inc.
    Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai
  • Publication number: 20160159905
    Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Application
    Filed: December 3, 2015
    Publication date: June 9, 2016
    Inventors: Yasmina Noubia ABDICHE, Helen Kim CHO, Weihsien HO, Karen Ute JOOSS, Arvind RAJPAL, Sawsan YOUSSEF
  • Publication number: 20150246106
    Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.
    Type: Application
    Filed: March 13, 2015
    Publication date: September 3, 2015
    Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai
  • Patent number: 9066898
    Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: June 30, 2015
    Assignee: Pfizer Inc.
    Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai
  • Publication number: 20150125465
    Abstract: The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.
    Type: Application
    Filed: October 29, 2014
    Publication date: May 7, 2015
    Inventors: Joseph John BINDER, Helen Kim CHO
  • Patent number: 8895017
    Abstract: The present invention provides (a) isolated immunogenic HER-2 peptides capable of inducing immune responses against human HER-2 receptor; (b) isolated nucleic acid molecules encoding an isolated immunogenic HER-2 peptide; (c) plasmid constructs comprising a nucleic acid molecule encoding an isolated immunogenic HER-2 peptide; (d) vaccine compositions comprising an isolated immunogenic HER-2 peptide (e) vaccine compositions comprising an isolated nucleic acid molecule encoding an isolated immunogenic HER-2 peptide; and (f) methods of treating or preventing cancer, inhibiting abnormal cell proliferation, or eliciting an immune response against HER-2 protein in a mammal using (1) an isolated immunogenic HER-2 peptide, (2) nucleic acid molecule encoding an isolated immunogenic HER-2 peptide, or (3) a composition comprising an isolated immunogenic HER-2 peptide, or composition comprising a nucleic acid molecule encoding an isolated immunogenic HER-2 peptide.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: November 25, 2014
    Assignee: Pfizer Inc.
    Inventors: Helen Kim Cho, Siradanahalli Chandrasekharalah Guru, Van To Tsai, Brian Gregory Pierce
  • Publication number: 20130295110
    Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.
    Type: Application
    Filed: May 1, 2013
    Publication date: November 7, 2013
    Applicant: PFIZER INC
    Inventors: Joseph John BINDER, Helen Kim CHO, Michael Robert DERMYER, Karin Ute JOOSS, Brian Gregory PIERCE, Joyce Tsi TAN, Van To TSAI
  • Publication number: 20130078270
    Abstract: The present invention provides (a) isolated immunogenic HER-2 peptides capable of inducing immune responses against human HER-2 receptor; (b) isolated nucleic acid molecules encoding an isolated immunogenic HER-2 peptide; (c) plasmid constructs comprising a nucleic acid molecule encoding an isolated immunogenic HER-2 peptide; (d) vaccine compositions comprising an isolated immunogenic HER-2 peptide (e) vaccine compositions comprising an isolated nucleic acid molecule encoding an isolated immunogenic HER-2 peptide; and (f) methods of treating or preventing cancer, inhibiting abnormal cell proliferation, or eliciting an immune response against HER-2 protein in a mammal using (1) an isolated immunogenic HER-2 peptide, (2) nucleic acid molecule encoding an isolated immunogenic HER-2 peptide, or (3) a composition comprising an isolated immunogenic HER-2 peptide, or composition comprising a nucleic acid molecule encoding an isolated immunogenic HER-2 peptide.
    Type: Application
    Filed: May 23, 2011
    Publication date: March 28, 2013
    Applicant: PFIZER INC.
    Inventors: Helen Kim Cho, Siradanahalli Chandrasekharalah Guru, Van To Tsai, Brian Gregory Pierce